secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXACT SCIENCES CORP (—)
CIK:        0001124140
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0001124140-24-000051
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Exact Sciences CCO Everett Cunningham departs; reaffirms Q2 and FY 2024 guidance
--------------------------------------------------------------------------------

- Chief Commercial Officer Everett Cunningham departing June 13, 2024 for a non-competing opportunity.
- Commercial organization reorganized under Screening and Precision Oncology teams; GMs Orville and Baranick continue.
- Reaffirmed Q2 2024 total revenue guidance of $677-697M; Screening $522-532M, Precision Oncology $155-165M.
- Reaffirmed full-year 2024 total revenue $2.810-2.850B and adjusted EBITDA $325-350M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124140/000112414024000051/0001124140-24-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124140/000112414024000051/exas-20240530.htm
  HTML page:      https://secwatch.observer/filing/0001124140-24-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer